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The hospital pharmacy in large and advanced institutions has evolved from a simple storage and distribution unit into a highly
specialized manipulation and dispensation center, responsible for the handling of hundreds of clinical requests, many of them
unique and not obtainable from commercial companies. It was therefore quite natural that in many environments, a manufacturing
service was gradually established, to cater to both conventional and extraordinary demands of the medical staff. That was the case
of Hospital das Clinicas, where multiple categories of drugs are routinely produced inside the pharmacy. However, cost-containment
imperatives dictate that such activities be reassessed in the light of their efficiency and essentiality.
Methods: In a prospective study, the output of the Manufacturing Service of the Central Pharmacy during a 12-month period
was documented and classified into three types. Group I comprised drugs similar to commercially distributed products, Group II
included exclusive formulations for routine consumption, and Group III dealt with special demands related to clinical investigations.
Results: Findings for the three categories indicated that these groups represented 34.4%, 45.3%, and 20.3% of total manufacture
orders, respectively. Costs of production were assessed and compared with market prices for Group 1 preparations, indicating
savings of 63.5%. When applied to the other groups, for which direct equivalent in market value did not exist, these results would
suggest total yearly savings of over 5 100 000 US dollars. Even considering that these calculations leave out many components of
cost, notably those concerning marketing and distribution, it might still be concluded that at least part of the savings achieved were
real.
Conclusions: The observed savings, allied with the convenience and reliability with which the Central Pharmacy performed
its obligations, support the contention that internal manufacture of pharmaceutical formulations was a cost-effective alternative in
the described setting.
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Large university-affiliated tertiary
hospitals, like Hospital das Clinicas,
are service-related institutions respon-
sible for the provision of complex
health assistance to many of the sick-
est segments of the population. At the
same time, they participate in teaching
and training responsibilities for gradu-
ate and postgraduate students and fel-
lows, and are involved with multiple
clinical and experimental investigation
protocols.
These roles represent a radical de-
parture from the historical origins of
nosocomial units as organizations for
charity, hospitality, and beneficence
maintained by religious orders or
wealthy donors, and not responsive to
anybody in particular except to the
conscience and moral principles of its
governing board, towards a modern
economic unit concerned with rational
organization, lean structure, specialized
personnel, technical expertise, external
audits, cost-efficient performance, and
high productivity1. All such aspects
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have a bearing on the functions of the
Central Pharmacy, especially when it is
engaged in manufacture in addition to
dispensation of medicines. In such cir-
cumstances it must adapt itself to new
and demanding challenges, and fulfill
all the expectations of a modern com-
mercial and industrial department, in
addition to its traditional activities.
Still, teaching hospitals are not
typical businesses, in the sense that
economical considerations are essential
but not always of paramount impor-
tance in the decision-making process.
Their merchandise is human life,
which is priceless; their shareholders in
a larger sense are the entire community
they are serving. Possibly more numer-
ous legal, moral, and professional
codes and regulations apply to their
routines than to any other human en-
deavor, and many of these have the po-
tential for interfering with financial re-
sults.
The Manufacturing Service of the
Central Pharmacy is not free from
these constraints; scientific, social,
and ethical considerations are often as
important determinants of its
workload as are technical and eco-
nomical duties with regard to hospi-
tal departments and needs of internal
and external patients.
Within the sometimes opposing
contexts of utmost cost-efficiency ex-
pected from modern organizations and
large expenditures dictated by unprof-
itable humanistic responsibilities, a
conflict of interests could arise within
the pharmacy. Indeed many controver-
sial views of its future are currently
debated2-4. The doubts become even
more serious when one considers that
preparation of pharmaceutical formu-
lations is not an obligatory role of the
hospital pharmacy nowadays, since ex-
ternal companies could be requested to
supply such items, rendering its re-
sources free for other purposes.
Aiming to contribute to the discus-
sions about the place of drug manipu-
lation and industrialization in a mod-
ern pharmacy, a prospective cost-evalu-
ation study was done during a 12-
month period, covering the entire
physical and economical manufactur-
ing output of the Central Pharmacy.
These results were compared with the
alternative of purchasing the same
products from commercial sources,
whenever available.
MATERIALS   AND   METHODS
Total drug deliveries of medicines
manufactured by the Central Pharmacy
of Hospital das Clinicas were docu-
mented in the period of January 1st –
December 31st, 1999, according to unit
type and pharmaceutical category. This
output was stratified in three groups:
Group I – Pharmaceutical preparations
ordinarily made by the Pharmacy simi-
lar to commercially distributed prod-
ucts; Group II – items routinely manu-
factured with exclusive formulations,
not available in the market; Group III
– new and experimental drugs, mix-
tures or presentations expressly des-
tined to approved clinical protocols.
Methods included systematic com-
puting of all orders processed by the
Central Pharmacy in the year of 1999,
classified as mentioned before, along
with preliminary cost estimation, both
of internal expenditures, and of corre-
sponding market price.
Cost calculation - Commercial
items were entered in accordance with
published manufacturer’s lists, updated
for December 31, 1999. The same date
was considered for internal costs, di-
vided into 4 categories: a) Raw mate-
rials; b) Packaging ; 3) Materials con-
sumed during industrial or manipula-
tion processes; 4) Approximate labor
costs. All values were converted into
US dollars.
These amounts represent main di-
rect and indirect expenditures, and ex-
clude other costs (financing, taxes,
commercialization, profits, and miscel-
laneous overheads).
Preliminary considerations
Over the years the Manufacturing
Service has established 7 different
lines, geared to the principal needs of
the institution: small-volume
parenterals (SVP), large-volume
parenterals (LVP), oral solutions (OS),
non-oral solutions (NOS), hemodialy-
sis fluids (HDF), solid items (SI), and
semi-solid products (SSP). Numeri-
cally, the principal demand is for solid
items (oral drugs in the form of pills,
tablets, and capsules), but it is either
small-volume parenterals (injectable
drugs) or large-volume parenterals
(principally parenteral nutrition mix-
tures) that usually embody the largest
economical value. In the present study,
the same lines are adopted in the cal-
culation of total production.
RESULTS
A grand total of 340 types of items
were manufactured by the Manufactur-
ing Service during the analyzed period.
Only 117 had similar commercially
available preparations (34.4%),
whereas 154 were exclusive formula-
tions (45.3%). Moreover, 69 requests
for investigations were delivered
(20.3%), all related to unusual and
non-marketed drugs, fluids, or presen-
tations. The discrimination of the nu-
merical and financial equivalent for
each of these modalities is shown in
tables 1, 2, and 3, as well as in charts
1,2, and 3.
Commercial value was directly
transcribed from public lists with re-
gard to components of Group I. Group
II and III items defied attempts to ob-
tain a faithful quotation; therefore, the
differences in prices were primarily
calculated for Group I. The total value
of US $3,039,953.86 represents a
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63.5% savings with regard to external
purchase. If by hypothesis the same
savings were achieved in all groups
(total amount $2,930,616.63), over
$5,100,000.00 would have to be
credited to the Manufacturing Service
during the studied period.
DISCUSSION
The ultimate goal of nosocomial
institutions, including the pharmacy,
which is a central part of these organi-
zations, is to improve sick people’s
lives through therapeutic interventions
to reduce morbidity, combat mortality,
and foster quality of life. Modern eco-
nomic realities mandate that this is to
be accomplished in the least expensive
way.
Employing a simplified economic
analysis in the pharmacy, one can de-
fine inputs, outputs, and productivity,
which is the relationship between the
former and the latter. The investment
or input encompasses such factors as
facilities, specialized equipment, per-
sonnel, administrative costs, drugs and
other materials that are purchased or
utilized in order to properly operate a
central pharmacy with manipulation
responsibilities. The direct result
should be a profitable balance sheet
with high productivity and few losses
or unnecessary expenditures. However,
all these are worthless if they are not
compatible with good quality of care
and high standards of medical assis-
tance, which are more difficult to mea-Chart 1 - Percentage distribution of drug categories.
Table 1 - Products similar to commercial formulations (Group I).
Modality Units Internal cost (US$) Commercial price (US$)
Small volume parenterals 1,977,333 560,825.15 2,672,654.92
Large volume parenterals 24,803 91,500.89 69,277.55
Oral solutions 118,913 87,895.28 135,138.32
Non-oral solutions 70,469 132,128.47 143,388.12
Hemodialysis fluids 42,920 280,229.79 559,592.65
Solid items 13,904,694 537,978.68 1,081,046.96
Semi-solid products 32,364 55,019.49 124,433.08
Total 16,171,496 1,745,577.74 4,785,531.60
Manufactured items that were also available in the market are listed.
Table 2 - Industrial output of exclusive formulations (Group II)*.
Modality Units Internal cost (US$)
Small volume parenterals 554,890 225,987.38
Large volume parenterals 50,161 443,390.69
Oral solutions 14,600 23,164.04
Non-oral solutions 30,470  124,086.83
Hemodialysis fluids ———— ——————
Solid items 3,233,752 166,090.98
Semi-solid products 36,759 99,446.41
Total 3,920,632 1 082,166.33
(*) No market value could be assessed for this category.
Routinely produced exclusive items are included.
Table 3 - Orders for research projects (Group III)*.
Modality Units Internal cost (US$)
Small volume parenterals 15,406 24,311.80
Large volume parenterals 4,230 33,185.18
Oral solutions - -
Non-oral solutions 4,726 11,739.19
Hemodialysis fluids 25 271.58
Solid items 436,582 31,895.33
Semi-solid products 517 1,469.47
Total 461,486 102,872.55
(*) Commercial value not available for comparison.
Non-routine requests experimental mixtures are displayed.
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sure because they are not easily trans-
lated to money, and their impact tends
to become clearly visible only on a
long term basis.
  In recent years, medical outcomes
have evolved into a sub-specialty,
which attempts to quantify these intan-
gibles that were previously alluded
to5,6. Morbidity, mortality, functional
changes, psychosocial results, scientific
achievements, and patient and commu-
nity satisfaction all build the reputation,
prestige, and esteem of the institution,
which are perhaps the best yardstick
for its performance and total value. A
similar view was provided by Lohr7,
who devised some years ago the five
“Ds” of outcome: Death, Disease, Dis-
ability, Discomfort, and Dissatisfac-
tion. One last but not least relevant “D”
should be Deficit, which does not al-
ways affect the patient personally, but
is of major concern to family, society,
and government, depending on who
foots the bill, and may severely inter-
fere with operative conditions of the
hospital and its pharmacy.
  It is certainly difficult to avoid the
constraints imposed by paying third-
parties, who demand lean structures and
rock-bottom costs for medications, but
at the same time do not admit compro-
mises of quality in manufacturing, stor-
age, distribution, dispensation, and other
services. Obviously, only the very lat-
est advances in pharmacological and
clinical investigation should be deliv-
ered, and personnel should have exper-
tise in all fields of drug manipulation
and therapy. And yet, how these aims
can possibly be reached within an en-
vironment of cost-containment, and
who should financially support them, is
rarely given sufficient consideration1-3.
  Some preventive and corrective
steps are sensible and should always be
adopted, namely those related to ratio-
nalization of pharmacy resources. Ar-
eas of both overutilization and
underutilization of equipment and per-
sonnel are economically inconvenient
and should be identified to adjust pro-
duction lines to quantitative demand. In
the first case, excessive consumption of
certain drugs may lead to delays in pro-
duction, poor quality control, and in-
creased stress for technicians and phar-
macists. The opposite situation
(underutilization) will represent a wast-
age of time and money, or even worse,
may deprive patients of needed ser-
vices because of poor allocation of
available resources3,6 .
 Optimization of all methods and
procedures—removing inefficiencies
and bottlenecks, abolishing unneces-
sary paperwork, and rationalizing
fluxes of people and materials—is an
indisputable maneuver for streamlining
output of pharmaceutical products.
This optimization contributes to in-
creased productivity and may save ma-
jor amounts of money. In the specific
situation of the Central Pharmacy of
Hospital das Clinicas, ideal conditions
for utilization of resources and im-
provement of methods and procedures
do not always exist, due to technical
and administrative limitations inherent
in public institutions. Still, there is an
ongoing effort to update systems, con-
sider new production routines, and
overcome barriers that might hamper
drug output or jeopardize quality of the
end products1-3.
Chart 3 - Comparative analysis of internal versus market costs (Group I).
Chart 2 - Estimated cost of manipulated products.
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True final costs of pharmacy ser-
vices are difficult, if not impossible to
ascertain. In private organizations, they
are eventually defined by the market,
in the sense that what is charged is as
much (or as little) as competitors and
consumers will allow. The number of
factors involved in pricing is enormous,
including many types of overhead or
general expenses, hidden or “black
box” items such as provision for future
expansion or renovation, and coverage
for bad debts or failed reimbursement,
plus distribution costs, which are very
pertinent in the present study8,9.
Indeed, all internal values here dis-
played (Tables 1, 2, and 3) embody only
principal direct and indirect expendi-
tures, and explicitly exclude commer-
cialization costs, which can reach very
significant levels. Advertisement, mar-
keting, delivery, sales taxes, profits, and
commissions for the sales chain often
double the initial estimates for drug
prices. In this setting, it is not unreason-
able to imagine that most of the savings
here achieved could simply correspond
to the fact that internal production in-
stead of external purchase was the se-
lected alternative, thus bypassing the
mentioned distribution charges.
Nevertheless, the fact is that the in-
vestments for establishing and maintain-
ing the Manufacturing Service of the
Central Pharmacy of Hospital das
Clinicas have long been completed and
the unit is in full operation. Even if this
was not reason enough for using it, the
current demonstration that approxi-
mately two/thirds of its output deal with
exclusive formulations or pharmaco-
logical agents essential for clinical in-
vestigations should justify its continuing
activities. These products have no im-
mediate substitute in the market, and it
is expected that the institution would
have to pay a substantial surcharge, and
probably incur great delays and logis-
tic problems, to order them elsewhere.
A university-affiliated hospital does
not have the obligation for spending a
share of its budget to sustain advertise-
ment, marketing, and sales teams of
external purveyors, and perhaps not
even commercial hospitals should en-
tertain this possibility, when pharma-
ceutical items can be successfully pro-
vided by internal manipulation. The
opposite hypothesis would only make
sense if estimated internal costs came
close to market prices, thus suggesting
that total real costs were equal to, or
greater than external ones, especially
within a context of aggressive purchas-
ing policies, which would probably
wipe out any remaining differences3,4.
The temptation to abolish manufac-
turing responsibilities cannot be under-
estimated in busy and understaffed ser-
vices, especially because this is not a
fundamental activity for the hospital
pharmacy. According to modern theo-
ries of business management, non-core
endeavors are best redistributed to spe-
cialized third-parties, who in principle
can do it better and cheaper.
Under the conditions of this project,
only a few answers can be anticipated
for these complex issues, and future
studies will be mandatory. Yet, in the
light of the composition, quantity, nomi-
nal cost, and estimated external cost of
principal categories of drugs fabricated
by the Manufacturing Service, it stands
to reason that the present system has
been doing an outstanding job. It has
catered not only to standard requests but
principally to exclusive and out-of-the-
market demands of a large, university-
associated hospital, while at the same
time achieving important savings. The
need for future changes and adjustments
cannot be ruled out; indeed progress is
always welcome, as long as it is pre-
ceded by careful assessment of expected
gains and possible losses1,3,4,8.
CONCLUSIONS
The analysis of manipulation of
pharmaceutical formulations by the
Central Pharmacy has permitted the
following conclusions:
1) The majority of preparations manu-
factured by the Central Pharmacy
corresponded to drugs without
similar preparations available com-
mercially: in addition to other ex-
clusive items related to clinical
studies, they represented about two-
thirds of total output;
2) Direct comparison of internal and
external costs confirmed savings of
63.5% for commercially available
formulations. If computed for the
entire production, a yearly balance
of over US $5 000 000 in favor of
the hospital would have been
reached;
3) In the light of these findings, there
are reasons to believe that industrial
manipulation of drugs by the Cen-
tral Pharmacy has been a beneficial
and cost-effective process.
RESUMO RHCFAP/3034
MARIN MLM e col. - Custo de medica-
mentos produzidos pelo Hospital
Universitário, papel da Farmácia
Central. Rev. Hosp. Clín. Fac.
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A Farmácia Hospitalar em institui-
ções avançadas e de grande porte evo-
luiu de uma simples unidade de arma-
zenamento e distribuição, para um cen-
tro de manipulação altamente especi-
alizado, responsável pelo proces-
samento de centenas de requisições
clínicas, muitas delas únicas e não dis-
poníveis de fontes comerciais. Foi per-
feitamente natural portanto que em
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muitos ambientes, um Serviço Indus-
trial fosse gradualmente estabelecido,
visando responder a demandas tanto
convencionais como extraordinárias da
equipe médica. Tal foi o caso do Hos-
pital das Clínicas, onde múltiplas ca-
tegorias de fármacos são rotineiramen-
te elaboradas nas dependências da Far-
mácia. Entretanto, imperativos de con-
tenção de gastos determinam que tais
atividades sejam reajuizadas sob o pris-
ma de sua eficiência e essencialidade.
Métodos: Num estudo prospectivo,
a produção do Serviço Industrial da
Farmácia Central durante um período
de 12 meses foi documentada, e clas-
sificada em três modalidades. O Gru-
po I abrangia medicamentos similares
a outros fornecidos comercialmente, no
Grupo II foram listadas formulações de
composição exclusiva, e finalmente o
Grupo III espelhava pedidos especiais
voltados para investigações clínicas.
Resultados: Os achados das diver-
sas categorias assinalaram que 34,4%,
45,3% e 20,3% dos medicamentos ela-
borados correspondiam a estes três gru-
pos, respectivamente.Os custos indus-
triais foram calculados para os
fármacos do Grupo I e comparados
com valores de mercado, chegando-se
a uma economia de 63,5%.Quando
extrapolada para os outros dois grupos,
relativamente aos quais não se conta-
va com preços comerciais diretamente
equivalentes, atingiu-se uma estimati-
va superior a 5 100 000 dólares de eco-
nomia durante um ano de operação.
Mesmo levando-se em conta que tais
contas deixaram de lado muitos custos,
notavelmente aqueles subordinados à
comercialização e distribuição, foi lí-
cito concluir que pelo menos parte da
economia citada era verdadeira.
Conclusões: A economia observa-
da, em combinação com a eficiência e
confiabilidade com que a Farmácia de-
sempenhou suas obrigações, vieram ao
encontro do ponto de vista de que a
manufatura interna de drogas foi uma
alternativa vantajosa sob o prisma de
custos, no contexto descrito.
DESCRITORES: Custo. Conten-
ção de custo. Farmácia hospitalar.
Manipulação de drogas. Industriali-
zação de drogas. Hospital Universi-
tário.
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